FDA reviews the safety of Januvia, Byetta, and other GLP-1 diabetes drugs

Interviewed by Steven E. Greer, MD

Janet Woodcock, MD, the FDA’s Director of CDER (in charge of all new drugs) discusses the safety review for GLP-1 agonist diabetes drugs, such as Januvia and Byetta.

This entry was posted in - Pharma, FDA. Bookmark the permalink.

Leave a Reply

Your email address will not be published. Required fields are marked *